A bill to expand the tropical disease product priority review voucher program to encourage prevention and treatment of coccidioidomycosis.

This bill adds coccidioidomycosis (Valley fever) to the list of diseases eligible for the FDA's priority review voucher program. The voucher program gives drug companies faster FDA review for new treatments in exchange for developing medicines for neglected tropical diseases. By including coccidioidomycosis, the bill directly encourages pharmaceutical companies to develop new prevention and treatment options for this fungal infection. This primarily affects drug developers and patients in regions where coccidioidomycosis is common, such as the southwestern United States.